Navigation Links
Asian Medical Markets Expert to Attend the MD&M Midwest Conference
Date:9/23/2010

BETHESDA, Md., Sept. 23 /PRNewswire/ -- Pacific Bridge Medical will be attending the Medical Design and Manufacturing (MD&M) Midwest Conference from September 28-30, 2010, at the Donald E. Stephens Convention Center in Rosemont, Illinois.

MD&M Midwest is part of a national conference series for professionals in R&D, design, engineering, manufacturing, and regulatory affairs within the pharmaceutical and medical device manufacturing industry. The conference is designed to provide information and insights that attendees can immediately apply to their job responsibilities.

Pacific Bridge Medical can be found in the exhibit hall at Booth 4733 and can offer attendees insight into quality management systems in Asia's regulatory environment and sourcing and manufacturing in Asia.  Company representatives will also provide detailed information regarding inquiries about Pacific Bridge Medical's services in Asia, particularly in Japan, China, India, and the ASEAN countries.

For more information about these topics visit the following pages:


About Pacific Bridge Medical

Pacific Bridge Medical was established in 1988 to assist international medical companies with doing business in Asia. Since then, Pacific Bridge Medical has helped hundreds of medical companies with business development and regulatory issues in Asia. Visit http://www.pacificbridgemedical.com for more info
'/>"/>

SOURCE Pacific Bridge Medical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
2. Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women
3. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
4. Cancer Treatment Guidelines for Diverse Asian Economies Use Model Developed at Fred Hutchinson Cancer Research Center
5. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
6. Asian Medical Markets Expert to Speak at the Wells Fargo Investor Forum
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Globus Medical Raises $110 Million in Series E Financing Round
11. Quark Pharmaceuticals Appoints New Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Juno Therapeutics today announced that the FDA ... JCAR015 chimeric antigen receptor product candidate.  The designation ... B-cell acute lymphoblastic leukemia and was filed by ... where Phase 1 clinical trials are currently underway. ... news for patients who may benefit from the ...
(Date:11/24/2014)... Nov. 24, 2014 Luoxis Diagnostics, Inc., ... AMPE), today announced the presentation of three clinical ... as a broadly applicable and robust research tool ... body in response to injury, illness, or stress.  ... collaboration with Luoxis, academic and pharmaceutical research partners, ...
(Date:11/24/2014)... Nov. 24, 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced today that Sergio Traversa ... the LD MICRO "MAIN Event" Micro-Cap Growth Conference on ... at the Luxe Sunset Bel Air Hotel, which is ... Angeles, California . The presentation is ...
Breaking Medicine Technology:Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5Relmada Therapeutics To Present At LD MICRO Conference 2
... Oct. 31, 2011 Covance Inc. (NYSE: ... ranked first, by a wide margin, in an independent ... trials. The majority (54 percent) of the study participants ... central laboratory, with investigators citing Covance three times more ...
... InterMune, Inc. (NASDAQ: ITMN ) today ... Shire plc, has been appointed to InterMune,s Board of ... on meeting the needs of the specialist physician. ... a leading global biopharmaceutical company with expertise in the ...
Cached Medicine Technology:Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 2Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 3InterMune Appoints Angus C. Russell to Board of Directors 2InterMune Appoints Angus C. Russell to Board of Directors 3
(Date:11/24/2014)... From embedded sensors and biometrics to elite training and ... center stage at the FitnessTech Summit , presented by ... International CES® , January 6, 2015 in Las Vegas (8:30am ... bond between fitness and technology is stronger than ever as ... about the human body. , “Fitness technology has become a ...
(Date:11/24/2014)... PA (PRWEB) November 24, 2014 ... Nataliya Ternopolska, MD has joined The Neurology Group ... Health’s Multiple Sclerosis Center. , A graduate of ... in Neurology at Albert Einstein Medical Center in Philadelphia ... Judith Jaffe Multiple Sclerosis Center at Weill Cornell Medical ...
(Date:11/24/2014)... November 24, 2014 The Holiday Inn ... Family and Children's Association to donate various ... shampoo, mouthwash and other such items.The Association's program is ... home bound, living in nursing homes, assisted living facilities ... enhance the well being of seniors throughout the Long ...
(Date:11/24/2014)... Longmont, CO, and Philadelphia, PA (PRWEB) November 24, ... a provider of care coordination and disease management ... organizations, has chosen to implement Essette’s Medical Management ... powerful new Essette SaaS platform in a program ... latest Essette suite includes Population Health Management, Care ...
(Date:11/23/2014)... a well-known wedding dress manufacturer, has unveiled its new collection ... now offered at deeply discounted prices, up to 75 percent ... 15. The main purpose of the promotion is to expand ... are ideal options for ladies who are eager to look ... new mint cocktail dresses are very beautiful; they are made ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2
... Demonstrates a 20-Meter Improvement in Six-Minute Walk ... Distance ... Time on November 1, 2007, SILVER SPRING, Md., Nov. 1 ... Rx, Inc., announced today the completion of their TRIUMPH-1 Phase 3,trial ...
... Calif., and WHITEHOUSE STATION, N.J., Nov. 1, Dynavax ... Co., Inc. (NYSE: MRK ) today announced ... develop HEPLISAV(TM), a,novel investigational hepatitis B vaccine, which ... clinical trial involving adults and in,patients on dialysis. ...
... 1 The makers of the WaveSense line ... Claudio,Carboni, formerly of Menarini Diagnostics, has joined as ... WaveSense Europe will,distribute the company,s high accuracy, WaveSense ... market both directly and through local,partners. Carboni ...
... Upload Video Confessions/ Testimonials for ... PHILADELPHIA and LONDON, Nov. 1 Thomson,Scientific, ... ; TSX: TOC) and,leading provider of information solutions ... the launch of its new campaign,"Confessions ... of ...
... (MHS), a not-for-profit health care system with hospitals ... it has selected,Integrated Healthcare Holdings, Inc. (IHHI) to ... partially physician-owned publicly traded hospital management,company, owns and ... total of,770 beds, 2787 employees and 1725 active ...
... Oct. 31 Always Best Care Senior,Services has expanded ... Living Placement Service, and Personal Response Company, is,proud to ... Always Best Care,Senior Services for outstanding care. For over ... our work - a sincere concern for,the betterment of ...
Cached Medicine News:Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 2Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 3Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 4Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 5Health News:Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint 6Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 2Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 3Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 4Health News:Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3 5Health News:Ex-Head of Menarini Diabetes Unit Launches WaveSense Europe 2Health News:Thomson Scientific Launches 'Confessions ... of a User' Campaign Asking 'Are You the New Face of Research?' 2Health News:Memorial Health Services Announces Sale of Anaheim Memorial Medical Center 2Health News:Announcing Always Best Care Senior Services Expansion Into San Diego, California 2
TBR-720-2-GD is large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standard AS38...
... direct competitive EIA for the quantitative ... or plasma. A specific agent displaces ... available for antibody binding. Testosterone then ... to fluorescein isothiocyanate (FITC) and alkaline ...
... Testosterone, (17-Hydroxy-4-androstene-3-one), a C19 steroid, is one ... [1]. In postpubertal males, testosterone is secreted ... small amount derived from peripheral conversion of ... been estimated that over 50% of serum ...
... testosterone exists as unbound or free testosterone. ... SHBG with high affinity [1], while the ... the albumin-bound and free fractions may be ... action. Measurement of the free or unbound ...
Medicine Products: